comparemela.com

Latest Breaking News On - Gsk plc - Page 5 : comparemela.com

GSK plc (NYSE:GSK) Q4 2023 Earnings Call Transcript

GSK plc (NYSE:GSK) Q4 2023 Earnings Call Transcript January 31, 2024 GSK plc misses on earnings expectations. Reported EPS is $0.72 EPS, expectations were $0.76. GSK isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Nick Stone: Hello, everyone. It’s Nick Stone, […]

GSK lifts long-term outlook following launch of blockbuster vaccine in 2023

GSK posts blowout RSV vaccine sales, raises outlook

The RSV shot, called Arexvy, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year. 

U K stocks drop Wednesday

GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine

Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter adjusted operating profit of £1.75 billion, up 10% at the actual exchange rate (AER) and up 21% at the constant exchange rate (CER). The company’s RSV vaccine, Arexvy, hit £1.2 billion in sales in 2023 and £529 million in the fourth quarter. Approximately 6 million of the 83 million U.S. adults aged 60 and older at risk have been vaccinated with Arexvy. The company reported sales of $10 billion (£8.1 billion), beating the consensus of $9.61 b

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.